UPDATE: Oppenheimer Raises PT on Health Management Associates and Reiterates Outperform Rating
Oppenheimer analyst Michael Wiederhorn published a report on Health Management Associates (NYSE: HMA) that reiterated its Outperform rating and raised the price target from $12 to $14.
Oppenheimer reported that, “Our 12-18 month price target of $14 equates to approximately 7X our 2014 EBITDA estimate of $1,001.8M, which is a discount to the historical industry average of 8.5X. We believe this discount is even more conservative when considering it does not include any potential upside to earnings from healthcare reform in 2015 and 2016.”
Shares of Health Management Associates close that $38.56 on Thursday.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.